Results 111 to 120 of about 113,823 (359)

A viable mouse model of factor X deficiency provides evidence for maternal transfer of factor X. [PDF]

, 2008
BackgroundActivated factor X (FXa) is a vitamin K-dependent serine protease that plays a pivotal role in blood coagulation by converting prothrombin to thrombin. There are no reports of humans with complete deficiency of FX, and knockout of murine F10 is
Arruda, VR, Chu, K, Golden, JA, Herzog, RW, High, KA, Labosky, PA, Margaritis, P, Tai, SJ   +7 more
core   +2 more sources

Sperm Sexing in Selected Animals and Humans: Methods, Applications, and Future Prospects

Andrology, EarlyView.
ABSTRACT Background Sperm sexing is a technique that enables the selection of offspring sex by sorting spermatozoa based on their sex chromosomes. This technology has gained increasing attention due to its potential applications in both animal breeding and human‐assisted reproduction.
Domrazek Kinga, Jurka Piotr
wiley   +1 more source

Current gynaecological management of women and girls with bleeding disorders in the United Kingdom: A UKHCDO haemophilia treatment centre survey and evaluation of real‐world clinical practice for the British Journal of Haematology

British Journal of Haematology, EarlyView.
Summary Girls and women with bleeding disorders (GWBD) comprise more than half of all registered patients with bleeding disorders in the UK National Haemophilia Database. The gynaecological care of GWBD, until recently, has not been prioritised despite high health burdens, where four of every five patients experience heavy menstrual bleeding (HMB).
Laura Knox, Imogen Swart‐Rimmer, Naim Rahimi, Callum Harris, Lugain Abdalla, Gary Benson, Clare Brown, Helen Campbell, Ana Carvalhosa, Justin T. Clarke, Sarah Garside, Claire Lentaigne, Jayna Mistry, Priyanka Raheja, Cora Warren, Rezan Abdul‐Kadir, Gill Lowe, Nicola Curry   +17 more
wiley   +1 more source

Comparative Investigation of Thromboelastometry and Thrombin Generation for Patients Receiving Direct Oral Anticoagulants or Vitamin K Antagonists

Diagnostics
Background. Alterations induced by direct oral anticoagulants (DOACs) or vitamin K antagonists (VKAs) to thromboelastometry and thrombin generation are not well defined.
Armando Tripodi, Marco Capecchi, Erica Scalambrino, Marigrazia Clerici, Barbara Scimeca, Pasquale Agosti, Paolo Bucciarelli, Andrea Artoni, Flora Peyvandi   +8 more
doaj   +1 more source

Suboptimal screening and correction of maternal iron deficiency anaemia in the general population and in inherited bleeding disorders: A population‐based cohort study

British Journal of Haematology, EarlyView.
Summary Iron deficiency anaemia (IDA) is associated with adverse pregnancy outcomes globally. Women with inherited bleeding disorders are at increased risk, with scarce data on rates of IDA screening and correction during pregnancy. The impact of correction on outcomes is unclear.
Arafat Ul Alam, Padma Kaul, Venu Jain, Cynthia Wu, Haowei (Linda) Sun   +4 more
wiley   +1 more source

Spontaneous bleeding in a patient with malignant lymphoma: A case of acquired hemophilia [PDF]

, 2000
Background: Acquired hemophilia is a rare condition which can be associated with lymphoproliferative disease. Case Report: Eleven yea rs after the diagnosis of immunocytoma had been made, a 72-year-old man developed a high-titer factor VIII inhibitor. At
Brack, N., Geiersberger, U., Gesierich, Wolfgang, Hartenstein, R., Munker, Reinhold, Pohlmann, H.   +5 more
core   +1 more source

Developing BIVV001, a new class of factor VIII replacement for hemophilia A that is von Willebrand factor-independent.

Blood, 2020
Factor VIII (FVIII) replacement products enable comprehensive care in hemophilia A. Treatment goals in severe hemophilia A are expanding beyond low annualized bleed rates to include long-term outcomes associated with high sustained FVIII levels.
Ekta Seth Chhabra, Tongyao Liu, J. Kulman, Susannah L Patarroyo-White, Buyue Yang, Qi Lu, Douglas Drager, Nancy Moore, Jiayun Liu, Amy M. Holthaus, J. Sommer, Ayman Ismail, Deana Rabinovich, Zhan Liu, A. van der Flier, A. Goodman, Christopher M. Furcht, Mark Tié, Tyler Carlage, R. Mauldin, Terrence M. Dobrowsky, Z. Liu, Oblaise A. Mercury, Lily Zhu, B. Mei, V. Schellenberger, Haiyan Jiang, G. Pierce, Joe Salas, R. Peters   +29 more
semanticscholar   +1 more source

Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐PROTECT Main Study

European Journal of Haematology, EarlyView.
ABSTRACT Background In the earlier PROTECT VIII Kids study (NCT01775618), damoctocog alfa pegol was efficacious for prevention and treatment of bleeds in children aged < 12 years with severe haemophilia A. Objective Assess the safety of damoctocog alfa pegol, including hypersensitivity and loss of efficacy (LoE) due to an immune response to ...
Margareth C. Ozelo, Matteo Luciani, Heidi Glosli, Kaan Kavakli, Nasrin Samji, Gregory C. Makris, Claudia Tueckmantel, Monika Maas Enriquez, Luciana C. Oliveira, Shveta Gupta, Mario Guillermo Arbesú, Mauro Davoli, Anthony K. C. Chan, Maria E. Mancuso   +13 more
wiley   +1 more source

Why is the uptake of gene therapy in hemophilia less than expected?

Research and Practice in Thrombosis and Haemostasis
Gene therapy has held promise to cure hemophilia since factor (F)VIII and FIX were cloned more than 40 years ago. However, scientific understanding of the adeno-associated virus, the predominant vector used in gene therapy, has been insufficient to ...
Glenn F. Pierce, Mark Skinner, Brian O’Mahony, Dawn Rotellini, Radoslaw Kaczmarek   +4 more
doaj   +1 more source

Emicizumab for the treatment of acquired hemophilia A.

Blood, 2020
Acquired hemophilia A (AHA) is a severe bleeding disorder caused by inhibiting autoantibodies to coagulation factor VIII (FVIII). For hemostatic treatment, bypassing agents, human or porcine FVIII are currently standard of care.
P. Knoebl, J. Thaler, P. Jilma, P. Quehenberger, K. Gleixner, W. Sperr   +5 more
semanticscholar   +1 more source